v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

EFFICACY OF INTENSIVE PHOTOTHERAPY IN MANAGEMENT OF TRANSFUSION IN JAUNDICE

AUTHORS:

Dr Ali Haider Tariq, Dr. Tayyaba Shahbaz, Dr Aiman Rasheed

ABSTRACT:

Introduction: Jaundice is observed during the 1st week after birth in approximately 60% of term infants and 80% of preterm infants. The yellow color usually results from the accumulation of unconjugated, nonpolar, lipid-soluble bilirubin pigment in the skin. Aims and objectives: The basic aim of the study is to analyze efficacy of intensive phototherapy in management of transfusion in jaundice. Material and methods: This cross sectional study was conducted at Jinnah Hospital, Lahore during June 2019 to January 2020. This study was consist of two groups one was including neonates with indirect hyperbilirubinaemia near the level of ECT and second was retrospective group who had been treated with conventional therapy. Results: The data were collected from 50 patients. Regarding gestational age, sex, mode of delivery, birth weight, and age on admission there was no statistically significant difference between the two groups. According to American Academy of Pediatrics guidelines our studied cases were classified into high, intermediate and low risk categories, in group 01 it was found that 28 (56%) cases in the high risk category; 12 cases (24%) in the intermediate risk category and 10 cases (20%) in the low risk category. Conclusion: It is concluded that use of intensive phototherapy in the management of pathological hyperbilirubinaemia is very effective in lowering total serum Bilirubin when its level is within 2-3 mg/dl (34-50 ╬╝mol/l) of the exchange transfusion level and in reducing the use of the invasive maneuver of exchange transfusion with its serious neurological complications.

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.